Gleevec Related Published Studies
Well-designed clinical trials related to Gleevec (Imatinib)
Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. [2008.06]
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. [2008.02.01]
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. [2007.12.01]
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. [2007.12]
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. [2007.09]
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. [2007.06.15]
Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). [2007.05.15]
The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. [2007.04]
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. [2007.03.20]
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. [2007.03.01]
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. [2006.12.07]
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. [2006.10.14]
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. [2006.10.10]
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. [2006.05]
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. [2006.02.28]
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. [2005.12.06]
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. [2005.08.20]
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. [2005.08]
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. [2005.07]
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. [2004.10]
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. [2004.09.25]
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. [2004.05]
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. [2004.04.15]
Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. [2004.02]
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. [2004.01.01]
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. [2003.12.01]
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. [2003.12]
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. [2003.12]
Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. [2003.11]
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. [2003.10.09]
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. [2003.08.23]
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. [2003.06.01]
[Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib] [2003.06]
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. [2003.06]
Quality of life on imatinib. [2003.04]
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. [2003.04]
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. [2003.03.13]
Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. [2003]
Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). [2002.10]
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. [2002.08.15]
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. [2001.10.27]
Well-designed clinical trials possibly related to Gleevec (Imatinib)
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour. [2008.05]
Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. [2008.03]
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. [2007.08.15]
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. [2007.07]
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. [2007.04.24]
Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. [2007.01]
An evidence-based approach to the management of pulmonary arterial hypertension. [2006.07]
Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. [2005.03]
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. [2004.03]
Other research related to Gleevec (Imatinib)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. [2008.10.27]
A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. [2008.10.25]
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. [2008.10.21]
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. [2008.10.01]
Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. [2008.09.30]
Phase II trial of imatinib mesylate in patients with metastatic melanoma. [2008.09.02]
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. [2008.09.01]
[Imatinib therapy in chronic myeloid leukemia] [2008.08.10]
Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia. [2008.08]
Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury. [2008.08]
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. [2008.07.22]
Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. [2008.07.10]
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. [2008.07.02]
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. [2008.07.01]
[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors.] [2008.07]
Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose? [2008.07]
Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. [2008.07]
O-Mel-Inib: A Cancero-pole Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma. [2008.06.13]
[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors.] [2008.06.12]
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. [2008.06.09]
A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. [2008.06.03]
Imatinib mesylate for the treatment of chronic myeloid leukemia. [2008.06]
Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment. [2008.06]
Effect of antacid on imatinib absorption. [2008.05.24]
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. [2008.05.20]
The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. [2008.05.15]
A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer. [2008.05]
Imatinib mesilate for the treatment of gastrointestinal stromal tumour. [2008.05]
Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. [2008.05]
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. [2008.03.15]
Resistance and relapse with imatinib in CML: causes and consequences. [2008.03]
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. [2008.02.18]
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. [2008.02.01]
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. [2008.02.01]
Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. [2008.02]
[Imatinib and solid tumours] [2008.01.01]
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. [2008.01.01]
The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. [2008]
[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study] [2008]
Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. [2008]
Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate. [2008]
Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis. [2008]
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. [2007.12.15]
Part II: management of resistance to imatinib in chronic myeloid leukaemia. [2007.12]
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. [2007.12]
Conjunctival hemorrhagic events associated with imatinib mesylate. [2007.12]
Strategies for overcoming imatinib resistance in chronic myeloid leukemia. [2007.12]
Management of imatinib-resistant CML patients. [2007.11]
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. [2007.11]
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. [2007.11]
[Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate] [2007.11]
|
